Skip to content
ETopical – Lifestyle
Author:
IGC Pharma, Inc.
IGC Pharma Unveils PRISM AI Platform to Move Alzheimer’s Risk Prediction to Brain-Health Action and Commercial Deployment
October 13, 2026
IGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer’s Trial; Topline Results Expected Q4 2026
September 28, 2026
IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer’s Trial Moves Within Six Randomizations of Enrollment Closure
August 18, 2026
IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer’s Trial Approaches Enrollment Closure and Q4 Topline Readout
August 11, 2026
IGC Pharma Evaluates Potential Recovery Options as Federal Jury Verdict Brings Renewed Attention to 2018 IGC Short Campaign
July 29, 2026
IGC Pharma to Showcase AI Portfolio at AAIC 2026, Including AHA Platform That Reduced Alzheimer’s Data Harmonization Time by 90% in Representative Workflow
July 9, 2026
IGC Pharma CEO and Principal Financial Officer Purchase More Than $1.15 Million of Common Stock Directly from the Company
July 7, 2026
IGC Pharma’s AHA Agentic AI Platform Reduces Alzheimer’s Data Harmonization Time by 90% in Representative Workflow
June 23, 2026
IGC Pharma Reaches Previously Disclosed 146-Patient Enrollment Target in Phase 2 CALMA Trial, Advancing Toward Topline Analysis
June 11, 2026
Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.50, Citing Clinical Progress and 2026 Catalysts
June 9, 2026
1
2
Next Page
→